HSTMNasdaqServices-Computer Programming, Data Processing, Etc.Fiscal year ends December 31
HEALTHSTREAM INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$33.31+0.18 (+0.54%)
Close on Oct 19, 2026
- Market cap
- $976.45M
- P/E (TTM)
- 46.3
- Dividend yield
- 0.37%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
64.7%+1.2 pts over 5 years
Operating margin
6.7%+0.2 pts over 5 years
Net margin
6.0%+0.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.3% | +4.5% | +4.4% | +3.8% | |
| Gross profit | +1.6% | +3.9% | +4.8% | – | |
| Operating income | -4.9% | +17.6% | +5.0% | +4.1% | |
| Net income | -8.3% | +14.9% | +5.4% | +7.8% | |
| EPS, diluted | -7.6% | +16.1% | +6.8% | +8.1% | |
| Free cash flow | +6.0% | +6.5% | +12.0% | +8.3% | |
| Dividend per share | +10.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 1.3% | 4.2% | 5.1% | |
| Return on assets | 1.0% | 2.8% | 3.6% | |
| Current ratio | 1.87 | 0.96 | 0.96 | |
| Capex to revenue | 2.5% | 0.8% | 1.2% | |
| Diluted shares | 32M | 32M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Healthstream generated $278.52M from operations and spent $89.79M on capital expenditure, dividends and share buybacks. 14% of that went back into the business.
Generated
$278.52M
Used
$89.79M
Capital expenditure$12.47M14%Dividends$10.22M11%Share buybacks$67.10M75%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.0%
×Asset turnover0.59×
×Equity multiplier1.45×
=Return on equity, FY20255.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.0% | 0.59× | 1.45× | 5.1% |
| FY2024 | 6.9% | 0.58× | 1.44× | 5.7% |
| FY2023 | 5.5% | 0.56× | 1.48× | 4.5% |
| FY2022 | 4.5% | 0.54× | 1.46× | 3.6% |
| FY2021 | 2.3% | 0.52× | 1.47× | 1.7% |
| FY2020 | 5.8% | 0.49× | 1.47× | 4.2% |
| FY2019 | 6.2% | 0.55× | 1.42× | 4.8% |
| FY2018 | 13.9% | 0.54× | 1.38× | 10.4% |
| FY2017 | 4.7% | 0.53× | 1.38× | 3.4% |
| FY2016 | 2.0% | 0.50× | 1.37× | 1.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$18.34M
- Cash generatingOperating cash flow above zero$63.32M
- Return on assets improvedROA up on the prior year4.0% → 3.6%
- Earnings backed by cashOperating cash flow above net income$63.32M vs $18.34M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.32 → 0.96
- No dilutionShare count did not rise31M → 30M
- Gross margin improvedGross margin up on the prior year66.42% → 64.74%
- More efficientAsset turnover rose0.58 → 0.60